AJP - Regulatory, Integrative and Comparative Physiology, Vol 273, Issue 4 1392-R1399, Copyright © 1997 by American Physiological Society

ARTICLES

Adrenomedullin in experimental congestive heart failure: cardiorenal activation

M. Jougasaki, T. L. Stevens, D. D. Borgeson, A. Luchner, M. M. Redfield and J. C. Burnett Jr
Division of Cardiovascular Diseases, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA.

Adrenomedullin (ADM) is a new member of a family of vasodilating and natriuretic peptides that plays an important role in cardiorenal regulation. This study was designed to establish the plasma, urinary, cardiac, and renal tissue concentrations and immunohistochemical localizations of ADM in normal dogs and dogs with experimental congestive heart failure (CHF) produced by rapid ventricular pacing. Plasma ADM concentration was 5.6 +/- 0.4 pg/ml in normal dogs and significantly increased to 14.5 +/- 2.5 pg/ml in CHF dogs (P < 0.05). Ventricular and renal tissue ADM were significantly increased in CHF dogs compared with normals. Immunohistochemical examination revealed positive ADM immunostaining within the myocytes, and ventricular ADM immunoreactivity was significantly more intense in CHF dogs than in normals. ADM immunoreactivity was also observed in the glomerulus, distal tubules, and medullary collecting duct cells in the kidney, and the intensities of ADM immunoreactivity in these sites were increased in CHF dogs compared with normals. In addition, ventricular ADM was a powerful marker for left ventricular mass, and circulating ADM correlated positively with left ventricular end-diastolic pressure and inversely with cardiac output and ejection fraction. Despite an increase in renal tissue ADM, urinary ADM did not increase in CHF dogs. The current study demonstrates that plasma concentration of ADM is increased in experimental CHF and that ventricular and renal ADM is activated in the progression of CHF. Tissue and circulating ADM also are markers for the alterations in myocardial structure and function. This study supports a potential role for ADM in the neurohumoral activation in experimental CHF.

This article has been cited by other articles:

				E. Bisping, G. Tenderich, P. Barckhausen, B. Stumme, S. Bruns, D. von Lewinski, and B. Pieske Atrial myocardium is the predominant inotropic target of adrenomedullin in the human heart Am J Physiol Heart Circ Physiol, November 1, 2007; 293(5): H3001 - H3007. [Abstract] [Full Text] [PDF]

				K. Nakanishi, H. Osada, M. Uenoyama, F. Kanazawa, N. Ohrui, Y. Masaki, T. Hayashi, Y. Kanatani, T. Ikeda, and T. Kawai Expressions of adrenomedullin mRNA and protein in rats with hypobaric hypoxia-induced pulmonary hypertension Am J Physiol Heart Circ Physiol, June 1, 2004; 286(6): H2159 - H2168. [Abstract] [Full Text] [PDF]

				D. O. McGregor, R. W. Troughton, C. Frampton, K. L. Lynn, T. Yandle, A. M. Richards, and M. G. Nicholls Hypotensive and Natriuretic Actions of Adrenomedullin in Subjects With Chronic Renal Impairment Hypertension, May 1, 2001; 37(5): 1279 - 1284. [Abstract] [Full Text] [PDF]

				F. Yoshihara, T. Nishikimi, I. Okano, T. Horio, C. Yutani, H. Matsuo, S. Takishita, T. Ohe, and K. Kangawa Alterations of Intrarenal Adrenomedullin and Its Receptor System in Heart Failure Rats Hypertension, February 1, 2001; 37(2): 216 - 222. [Abstract] [Full Text] [PDF]

				H. Romppanen, J. Puhakka, G. Foldes, I. Szokodi, O. Vuolteenaho, H. Tokola, M. Toth, and H. Ruskoaho Endothelin-1-Independent and Angiotensin II-Independent Induction of Adrenomedullin Gene Expression Hypertension, January 1, 2001; 37(1): 84 - 90. [Abstract] [Full Text] [PDF]

				J. G. Lainchbury, D. M. Meyer, M. Jougasaki, J. C. Burnett Jr., and M. M. Redfield Effects of adrenomedullin on load and myocardial performance in normal and heart-failure dogs Am J Physiol Heart Circ Physiol, September 1, 2000; 279(3): H1000 - H1006. [Abstract] [Full Text] [PDF]

				P. Solter, D. Sisson, W. Thomas, and L. Goetze Intrarenal Effects of Ecadotril during Acute Volume Expansion in Dogs with Congestive Heart Failure J. Pharmacol. Exp. Ther., June 1, 2000; 293(3): 989 - 995. [Abstract] [Full Text]

				M. Jougasaki and J. C. Burnett Jr Adrenomedullin as a renal regulator peptide Nephrol. Dial. Transplant., March 1, 2000; 15(3): 293 - 295. [Full Text] [PDF]

				M. Jougasaki, J. A. Schirger, R. D. Simari, and J. C. Burnett Jr Autocrine Role for the Endothelin-B Receptor in the Secretion of Adrenomedullin Hypertension, November 1, 1998; 32(5): 917 - 922. [Abstract] [Full Text] [PDF]